Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
TWST

TWST - Twist Bioscience Corp Stock Price, Fair Value and News

42.24USD+0.88 (+2.13%)Delayed

Market Summary

TWST
USD42.24+0.88
Delayed
2.13%

TWST Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

TWST Stock Price

View Fullscreen

TWST RSI Chart

TWST Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-12.8

Price/Sales (Trailing)

8.86

EV/EBITDA

-14.03

Price/Free Cashflow

-25.75

TWST Price/Sales (Trailing)

TWST Profitability

Operating Margin

38.29%

EBT Margin

-68.93%

Return on Equity

-34.3%

Return on Assets

-27.34%

Free Cashflow Yield

-3.88%

TWST Fundamentals

TWST Revenue

Revenue (TTM)

277.5M

Rev. Growth (Yr)

25.13%

Rev. Growth (Qtr)

5.32%

TWST Earnings

Earnings (TTM)

-192.1M

Earnings Growth (Yr)

23.1%

Earnings Growth (Qtr)

-5.78%

Breaking Down TWST Revenue

Last 7 days

-10.1%

Last 30 days

37.4%

Last 90 days

10.6%

Trailing 12 Months

182.4%

How does TWST drawdown profile look like?

TWST Financial Health

Current Ratio

5.51

Debt/Equity

0

Debt/Cashflow

-138.42

TWST Investor Care

Shares Dilution (1Y)

1.89%

Diluted EPS (TTM)

-3.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024277.5M000
2023227.8M235.5M245.1M262.4M
2022163.1M184.2M203.6M215.8M
2021113.0M126.8M132.3M146.2M
202065.8M73.4M90.1M101.1M
201940.0M47.1M54.4M60.1M
201818.1M21.8M25.4M32.6M
20170010.8M14.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Twist Bioscience Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 03, 2024
finn patrick john
sold
-85,816
37.134
-2,311
president and coo
May 03, 2024
banyai william
sold
-29,632
37.134
-798
see remark
May 03, 2024
werner robert f.
sold
-4,901
37.134
-132
chief accounting officer
May 03, 2024
leproust emily m.
sold
-154,589
37.134
-4,163
chief executive officer
May 03, 2024
cho dennis
sold
-21,092
37.134
-568
see remarks
May 03, 2024
green paula
sold
-33,791
37.134
-910
svp of human resources
Apr 23, 2024
finn patrick john
sold
-65,483
30.121
-2,174
president and coo
Apr 09, 2024
laponis adam
sold
-18,434
33.155
-556
chief financial officer
Apr 02, 2024
green paula
sold
-7,496
32.736
-229
svp of human resources
Apr 02, 2024
finn patrick john
sold
-16,106
32.736
-492
president and coo

1–10 of 50

Which funds bought or sold TWST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.33
134,875
380,875
0.05%
May 20, 2024
Virtu Financial LLC
sold off
-100
-526,000
-
-%
May 16, 2024
CASTLEARK MANAGEMENT LLC
added
11.79
196,317
5,030,880
0.21%
May 16, 2024
COMERICA BANK
reduced
-7.77
-10,808
65,566
-%
May 16, 2024
Virtus Investment Advisers, Inc.
unchanged
-
-22,960
308,927
0.22%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.49
-247,332
1,982,330
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-61.93
-2,696,600
1,479,890
-%
May 15, 2024
Royal Bank of Canada
reduced
-60.3
-422,000
247,000
-%
May 15, 2024
Schonfeld Strategic Advisors LLC
sold off
-100
-909,224
-
-%
May 15, 2024
GOLDMAN SACHS GROUP INC
reduced
-34.72
-10,608,700
16,429,800
-%

1–10 of 42

Are Funds Buying or Selling TWST?

Are funds buying TWST calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TWST
No. of Funds

Unveiling Twist Bioscience Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.49%
5,475,322
SC 13G/A
Feb 12, 2024
william blair investment management, llc
6.2%
3,549,874
SC 13G
Feb 12, 2024
nikko asset management americas, inc.
6.21%
3,583,443
SC 13G/A
Feb 12, 2024
artisan partners limited partnership
6.4%
3,723,305
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
6.21%
3,583,443
SC 13G/A
Jan 29, 2024
ark investment management llc
12.51%
7,213,257
SC 13G/A
Jan 25, 2024
state street corp
5.83%
3,362,215
SC 13G/A
Jan 25, 2024
jpmorgan chase & co
7.7%
4,462,494
SC 13G/A
Jan 25, 2024
jpmorgan chase & co
7.7%
4,462,494
SC 13G/A

Recent SEC filings of Twist Bioscience Corp

View All Filings
Date Filed Form Type Document
May 23, 2024
144
Notice of Insider Sale Intent
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 03, 2024
144
Notice of Insider Sale Intent
May 03, 2024
144
Notice of Insider Sale Intent
May 03, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Twist Bioscience Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
194.5B
23.7B
4.88% 13.96%
44.19
8.19
-8.94% -35.91%
44.1B
6.7B
9.51% 26.00%
35.7
6.55
-2.81% -6.58%
42.7B
3.7B
4.50% 12.76%
49.22
11.45
8.57% 23.94%
15.7B
9.3B
2.70% 6.46%
18.55
1.69
-3.29% 6.68%
13.5B
1.2B
19.72% 127.07%
-36.81
11.13
39.26% 33.08%
12.1B
2.0B
-1.77% 93.18%
38.72
6.16
25.57% 21.62%
11.2B
4.1B
-9.28% 11.45%
25.5
2.72
0.49% -11.59%
9.2B
2.5B
-21.19% -38.34%
-38.28
3.63
15.21% 53.51%
MID-CAP
3.1B
603.7M
41.05% -8.40%
-6.78
5.17
25.21% 30.68%
2.9B
929.2M
7.19% -19.98%
1.8K
3.09
28.93% 111.61%
SMALL-CAP
830.2M
275.1M
99.75% 97.03%
-4.53
3.02
-13.93% -126.97%
79.1M
31.1M
-5.13% -86.67%
-1.02
2.54
0.95% 19.75%
28.0M
9.2M
-33.82% -39.84%
-1.9
3.06
11.85% 45.80%
2.0M
5.5M
-58.54% 80.91%
-0.16
0.36
-68.52% -141.15%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Twist Bioscience Corp News

Latest updates
Defense World23 May 202410:24 am
Yahoo Finance02 May 202407:00 am
Seeking Alpha02 May 202407:00 am

Twist Bioscience Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue5.3%75,302,00071,498,00066,946,00063,740,00060,180,00054,243,00057,306,50056,113,00048,127,00042,018,00037,950,50035,018,00031,204,00028,161,00032,432,00021,207,00019,297,00017,164,00015,736,50013,600,00013,557,000
Cost Of Revenue4.4%44,420,00042,536,00042,424,00041,845,00041,669,00029,442,00031,586,00030,974,00029,714,00027,056,00022,497,00020,933,00019,028,00018,162,00017,577,50016,472,00013,564,00013,792,00012,385,50011,394,00011,789,000
Costs and Expenses4.8%124,191,000118,475,000117,057,500124,521,000121,817,00098,873,000114,177,500117,276,000108,929,00097,958,00077,761,50077,136,00069,208,00060,954,00056,399,00049,403,00051,383,00072,994,00047,305,00041,721,00039,820,000
  S&GA Expenses5.3%55,622,00052,840,00047,391,50046,057,00053,965,00042,324,00054,159,50053,693,00053,998,00051,098,00038,242,50034,478,00034,389,00028,792,00027,185,00022,487,00027,190,00026,405,00024,423,00021,320,00019,124,000
  R&D Expenses4.5%24,149,00023,099,00023,745,50024,528,00027,379,00031,242,00029,606,00036,840,00031,231,00022,630,00019,443,00019,838,00015,791,00014,000,00011,636,50010,444,00010,629,00010,297,00010,496,5009,007,0008,907,000
EBITDA Margin13.5%-0.57-0.66-0.71-0.77-0.83-0.91-1.04-1.11-1.15-1.14-1.09-1.01---------
Interest Expenses---1,0001,0002,0001,00025,500-29,00026,00083,50070,00095,000118,000143,000181,000215,000248,000287,500318,000340,000
Income Taxes187.5%345,000120,000-222,000622,000676,00076,000292,000-149,000-149,000-10,405,000340,500-2,377,00061,00046,000262,50021,00061,00037,000112,00054,00084,000
Earnings Before Taxes-5.3%-45,147,000-42,888,000-46,465,000-56,773,000-58,480,000-41,748,000-50,823,000-60,666,000-60,817,000-55,968,000-40,901,500-42,414,000-37,858,000-32,854,000-24,055,500-28,186,000-31,707,000-55,601,000-31,069,000-27,862,000-25,849,000
EBT Margin11.6%-0.69-0.78-0.83-0.88-0.93-0.99-1.12-1.19-1.23-1.21-1.16-1.08---------
Net Income-5.8%-45,492,000-43,008,000-46,243,000-57,395,000-59,156,000-41,824,000-51,115,000-60,517,000-60,668,000-45,563,000-41,242,000-40,037,000-37,919,000-32,900,000-24,318,000-28,207,000-31,768,000-55,638,000-31,181,000-27,916,000-25,933,000
Net Income Margin11.7%-0.69-0.78-0.83-0.89-0.93-0.99-1.07-1.13-1.15-1.13-1.15-1.07---------
Free Cashflow18.2%-20,026,000-24,479,000-23,097,000-27,921,000-53,341,000-65,894,000-17,729,000-74,767,000-74,310,000-59,436,000-42,892,000-34,902,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-4.1%7037337768108549109619801,022786702725677700399408324192187207140
  Current Assets-4.7%372390424446489542596624664385546577608634335345260129160183121
    Cash Equivalents-7.5%24626628630731531938037840919346747740135094.0020918527.0047.0069.0029.00
  Inventory-1.6%30.0031.0032.0036.0040.0045.0039.0043.0045.0040.0032.0021.0016.0013.0012.0013.0011.007.007.005.004.00
  Net PPE-3.9%12112613214114714513912792.0065.0044.0038.0032.0027.0025.0024.0023.0021.0021.0020.0015.00
  Goodwill0%86.0086.0086.0086.0086.0086.0086.0086.0086.0084.0022.0023.001.001.001.001.001.001.001.001.001.00
Liabilities0.0%14314315315315016417215915814012111563.0062.0063.0059.0060.0089.0035.0031.0025.00
  Current Liabilities3.5%67.0065.0073.0073.0072.0084.0091.0093.0085.0080.0063.0055.0040.0037.0036.0031.0030.0058.0030.0025.0019.00
  Long Term Debt--------------1.001.002.003.004.004.005.006.00
    LT Debt, Current-----------2.002.003.003.003.003.003.003.003.003.003.00
    LT Debt, Non Current--------------1.001.002.003.004.004.005.006.00
Shareholder's Equity-5.1%560590623658704746789821863626581610614638336349264103152176115
  Retained Earnings-4.2%-1,121-1,076-1,033-986-929-870-828-777-716-656-610-569-529-491-458-434-405-374-318-287-259
  Additional Paid-In Capital0.9%1,6821,6671,6571,6451,6331,6171,6201,5991,5811,2821,1911,1791,1431,129795783670477470463375
Shares Outstanding0.7%58.0058.0058.0057.0057.0056.0057.0056.0052.0050.0048.0048.00---------
Float-----833---2,390---4,885---1,088---402
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations15.5%-19,423-22,973-20,704-23,412-44,288-54,070-1,267-34,125-42,340-46,653-34,803-27,960-24,549-24,932-25,202-23,468-58,671-34,914-23,358-22,082-20,813
  Share Based Compensation25.4%13,82411,02011,74710,59710,259-2,32519,04820,04322,46518,1089,2479,17611,5537,0225,1314,0714,1973,6973,3633,0322,911
Cashflow From Investing-225.8%-5,2404,165-2,24718,67041,160-6,9712,7834,163-13,294-226,58223,911104,57573,590-45,921-94,669-61,14928,76312,405-1,187-22,706-15,160
Cashflow From Financing224.1%1,828-1,473442-6611,525-3951,240-1,311271,616-1,0111,575-7651,451326,9215,574108,064188,0372,0572,92884,285-1,634
  Buy Backs----------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TWST Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Revenues[1]$ 75,302$ 60,180$ 146,800$ 114,423
Operating expenses:    
Cost of revenues44,42041,66986,95571,111
Research and development24,14927,37947,24958,621
Selling, general and administrative55,62253,965108,46296,289
Change in fair value of contingent considerations and holdbacks0(1,196)0(5,331)
Total operating expenses124,191121,817242,666220,690
Loss from operations(48,889)(61,637)(95,866)(106,267)
Interest income3,9413,4648,0616,504
Interest expense0(2)0(3)
Other income (expense), net(199)(305)(230)(462)
Loss before income taxes(45,147)(58,480)(88,035)(100,228)
Income tax provision(345)(676)(465)(752)
Net loss attributable to common stockholders(45,492)(59,156)(88,500)(100,980)
Other comprehensive loss:    
Change in unrealized gain (loss) on investments(57)647771,516
Foreign currency translation adjustment(38)7319438
Comprehensive loss$ (45,587)$ (58,436)$ (88,404)$ (99,026)
Net loss per share attributable to common stockholders—basic (in usd per share)$ (0.79)$ (1.04)$ (1.54)$ (1.78)
Net loss per share attributable to common stockholders—diluted (in usd per share)$ (0.79)$ (1.04)$ (1.54)$ (1.78)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares)57,77956,77757,63756,608
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares)57,77956,77757,63756,608
[1]During the three and six months ended March 31, 2024, the Company generated revenues from related parties totaling of $3.2 million and $5.6 million, respectively. During the three and six months ended March 31, 2023, the Company generated revenues from related parties totaling $2.2 million and $2.6 million, respectively.

TWST Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Sep. 30, 2023
Current assets:  
Cash and cash equivalents$ 243,348$ 286,470
Short-term investments49,99449,943
Accounts receivable, net35,99344,064
Inventories30,37632,063
Prepaid expenses and other current assets12,15811,716
Total current assets371,869424,256
Property and equipment, net121,339131,830
Operating lease right-of-use assets63,66671,531
Goodwill85,81185,811
Intangible assets, net51,89854,483
Restricted cash, non-current2,8682,811
Other non-current assets5,3955,681
Total assets702,846776,403
Current liabilities:  
Accounts payable7,70314,052
Accrued expenses14,51310,754
Accrued compensation25,21425,818
Current portion of operating lease liability14,62114,896
Other current liabilities5,4397,803
Total current liabilities67,49073,323
Operating lease liability, net of current portion74,80479,173
Other non-current liabilities421475
Total liabilities142,715152,971
Commitments and contingencies (Note 6)
Stockholders’ equity  
Common stock, $0.00001 par value —100,000 and 100,000 shares authorized at March 31, 2024 and September 30, 2023, respectively; 58,162 and 57,557 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively00
Additional paid-in capital1,682,4731,657,222
Accumulated other comprehensive income(660)(756)
Accumulated deficit(1,121,682)(1,033,034)
Total stockholders’ equity560,131623,432
Total liabilities and stockholders’ equity$ 702,846$ 776,403
TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEtwistbioscience.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES989

Twist Bioscience Corp Frequently Asked Questions


What is the ticker symbol for Twist Bioscience Corp? What does TWST stand for in stocks?

TWST is the stock ticker symbol of Twist Bioscience Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Twist Bioscience Corp (TWST)?

As of Fri May 24 2024, market cap of Twist Bioscience Corp is 2.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TWST stock?

You can check TWST's fair value in chart for subscribers.

What is the fair value of TWST stock?

You can check TWST's fair value in chart for subscribers. The fair value of Twist Bioscience Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Twist Bioscience Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TWST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Twist Bioscience Corp a good stock to buy?

The fair value guage provides a quick view whether TWST is over valued or under valued. Whether Twist Bioscience Corp is cheap or expensive depends on the assumptions which impact Twist Bioscience Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TWST.

What is Twist Bioscience Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 24 2024, TWST's PE ratio (Price to Earnings) is -12.8 and Price to Sales (PS) ratio is 8.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TWST PE ratio will change depending on the future growth rate expectations of investors.